Policy & Regulation
Oncopeptides to present new data from phase 1/2 ANCHOR trail at 24th EHA Congress
17 June 2019 - Oncopeptides AB (STO:ONCO) on Friday announced the presentation of new data at the 24th Congress of the European Haematology Association (EHA) in Amsterdam, including updated interim da...
22nd Century Group promotes Michael J. Zercher to COO
17 June 2019 - Plant biotechnology company 22nd Century Group Inc (NYSE American:XXII) reported on Friday the election of Michael J. Zercher as its chief operating officer.In his new position, Zercher...
Concert Pharmaceuticals Reports Positive Results from Phase 1 Studies Evaluating CTP-692 in Healthy Volunteers
14 June 2019 - - US-based Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) has reported positive results from two studies in its Phase 1 programme evaluating CTP-692, a novel deuterium-modified form ...
Seattle Genetics Makes Multiple Adcetris Presentations at the Congress of the European Hematology Association and the International Conference on Malignant Lymphoma
14 June 2019 - - US-based biotechnology company Seattle Genetics, Inc. (NASDAQ: SGEN) is presenting data from its Adcetris (brentuximab vedotin) clinical development programme at the 24th An...
Prelude Therapeutics Secures USD 60m and Expands Management Team to Develop Drugs Targeting Novel Molecular Mechanisms in Cancer
14 June 2019 - - US-based biopharmaceutical company Prelude Therapeutics has secured USD 60m in series B financing; taking its total investments to date to USD 95m, the company said.
The financi...
New Phase 2 Clinical Trial Results Continue to Demonstrate Potential Clinical Benefit of IMV's DPX-Survivac in Combination with US Merck's Keytruda in Patients with DLBCL
14 June 2019 - - Canadian immuno-oncology corporation IMV Inc. (NASDAQ: IMV) (TSX: IMV) has released updated data from the ongoing investigator-sponsored SPiReL Phase 2 clinical trial assessing IMV�...